You are here: Industry Insights > Market News > Oncology biotech Tyra Biosciences files for a $100 million IPO

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

TaYaCn Drying Pumpkin powder CT-C series hot air circulation oven

TaYaCn Drying Lysimachia christinae CT-C series hot air circulation oven

TaYaCn Drying cabbage CT-C series hot air circulation oven

TaYaCn Drying Shrimp skin CT-C series hot air circulation oven

TaYaCn Drying Stone heat treatment CT-C series hot air circulation oven

TaYaCn Drying Banana slices CT-C series hot air circulation oven

Oncology biotech Tyra Biosciences files for a $100 million IPO

firstwordpharmaAugust 23, 2021

Tag: Tyra , FGFR , IPO

Favorites

Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.

The company is using its proprietary SN?P platform to generate next-generation candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options.

Its lead candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

Tyra anticipates filing an investigational new drug application for TYRA-300 in mid-2022.

Previous:South Korea to get more Moderna COVID shots in boost to vaccination effort

Next:UK scientists look at reducing boosters to save vaccine for rest of the world

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Oncology biotech Tyra Biosciences files for a $100 million IPO | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.